Research and Clinical Trials

Title  
RTOG 3508: A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification
Brief Description  
Phase 2b: Determine if the addition of ABT414 to concomitant radiotherapy and temozolomide prolongs progression free survival (PFS) among subjects with newly diagnosed GBM harboring EGFR amplification. Phase 3: To determine if addition of ABT414 to concomitant radiotherapy and temozolimide plus adjuvant temozolomide prolongs Overall Survival (OS) among subjects with newly diagnosed GBM harboring EGFR amplification.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Brain and Nervous System
Status  
OPEN
Start Date  
08/18/2016
IRB Number  
00016995
Principal Investigator  
Sumrall, Ashley Love
Contact Name  
Joey Armstrong

For More Information, Contact  Joey  , Armstrong
Phone:  980-442-2346 Fax:    
Email:  Joey.Armstrong@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, NC 28204
Close